Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
RESEARCH TOOLSreports
Holding ELDN?
Track your performance easily
ELDN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.11 - $5.54
Previous Close$3.85
Volume95.61K
Average Volume (3M)363.39K
Market Cap
$239.92M
Enterprise Value$154.10M
Total Cash (Recent Filing)$78.19M
Total Debt (Recent Filing)$501.00K
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Mar 27, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.71
Shares Outstanding59,739,275
10 Day Avg. Volume329,636
30 Day Avg. Volume363,390
Standard Deviation0.32
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.03
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda12.32
Forecast
1Y Price Target
$13.88Price Target Upside248.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Eledon Pharmaceuticals News
PremiumCompany Announcements
Eledon Pharmaceuticals Reports Strong Q3 2024 Results
PremiumCompany Announcements
Eledon Pharmaceuticals Announces $85 Million Stock Offering
PremiumCompany Announcements
Eledon Pharmaceuticals Reports Promising Trial Results for TegoprubartBulls Say, Bears Say
Bulls Say
Clinical TrialsTegoprubart continues to be generally safe and well-tolerated in the Phase Ib study, with no cases of hyperglycemia, new onset diabetes, or tremor.
Financial PerformanceMgmt. expects current cash and equivalents to fund operations through YE25, with potential to access an additional ~$50mn tranche of capital that could extend the cash runway into 2027 and through the Phase 2 POC readout.
Market OpportunityELDN sees a significant commercial opportunity for effective rejection-preventing medications, citing the blockbuster peak sales of current standard-of-care tacrolimus.
Bears Say
Clinical TrialsThree subjects have discontinued treatment due to hair loss and fatigue, viral infection, and rejection.
Health RisksFive cases of BK viremia and two cases of cytomegaloviremia have been reported.
Investment RisksRisks to the investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, and unproven commercialization strategy.
---
Ownership Overview
22.44% Insiders
2.48% Mutual Funds
23.09% Other Institutional Investors
49.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELDN FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was $1.11 and its highest was $5.54 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Currently, no data Available
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Mar 27, 2025 which is in 126 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.315 by -$0.005.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -$0.29.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 59,739,277 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.315. Following the earnings report the stock price went down -11.411%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Among the largest hedge funds holding Eledon Pharmaceuticals’s share is Woodline Partners LP. It holds Eledon Pharmaceuticals’s shares valued at 2M.
---
Eledon Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.88 (248.31% Upside)
$13.88 (248.31% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 167.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
215.57%
12-Months-Change
Fundamentals
Return on Equity
-119.41%
Trailing 12-Months
Asset Growth
19.26%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. (Nasdaq:ELDN) is an immunology-focused biotechnology company utilizing its experience in the CD40/CD40L costimulatory pathway to develop and commercialize precision therapies for persons undergoing organ and cellular transplantation, and for people living with autoimmune and neurodegenerative disease. The company’s lead compound in development is tegoprubart (AT-1501), an anti-CD40L antibody. The company, which was established in 2004, is headquartered in Irvine, CA.
---
ELDN Earnings Call
Q1 2023
0:00 / 0:00
---
ELDN Stock 12 Month Forecast
Average Price Target
$13.88
▲(248.31% Upside)
Technical Analysis
Best Analysts Covering ELDN
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+26.72%
reiterated a buy rating 2 days ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +26.72% per trade.
---